Citius Oncology (CTOR) Advances Commercial Shift With A Launch Update
After a significant development update, shares of Citius Oncology, Inc. (NASDAQ: CTOR) jumped 20.50% to $1.88 as of the most recent check. LYMPHIR, an immunotherapy licensed by the FDA to treat relapsed or refractory cutaneous T-cell lymphoma (CTCL), is nearly ready for commercialization. The announcement marks a major milestone in Citius’s transformation from a development-stage […]